Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Non-Current Deferred Tax Liability (2016 - 2024)

STRATA Skin Sciences' Non-Current Deferred Tax Liability history spans 9 years, with the latest figure at $186000.0 for Q3 2024.

  • For Q3 2024, Non-Current Deferred Tax Liability fell 39.22% year-over-year to $186000.0; the TTM value through Sep 2024 reached $186000.0, down 39.22%, while the annual FY2023 figure was $186000.0, 39.22% down from the prior year.
  • Non-Current Deferred Tax Liability for Q3 2024 was $186000.0 at STRATA Skin Sciences, roughly flat from $186000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $306000.0 in Q4 2022 and bottomed at $88000.0 in Q1 2020.
  • The 5-year median for Non-Current Deferred Tax Liability is $262000.0 (2021), against an average of $236947.4.
  • The largest annual shift saw Non-Current Deferred Tax Liability soared 513.64% in 2020 before it tumbled 39.22% in 2023.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $254000.0 in 2020, then grew by 4.72% to $266000.0 in 2021, then rose by 15.04% to $306000.0 in 2022, then crashed by 39.22% to $186000.0 in 2023, then changed by 0.0% to $186000.0 in 2024.
  • Per Business Quant, the three most recent readings for SSKN's Non-Current Deferred Tax Liability are $186000.0 (Q3 2024), $186000.0 (Q2 2024), and $186000.0 (Q1 2024).